This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease


Munro, Cynthia A., Longmire, Crystal Flynn, Drye, Lea T., Martin, Barbara K., Frangakis, Constantine E., Meinert, Curtis L., Mintzer, Jacobo E., Porsteinsson, Anton P., Rabins, Peter V., Rosenberg, Paul B., Schneider, Lon S., Weintraub, Daniel, Lyketsos, Constantine G.


The American Journal Of Geriatric Psychiatry: Official Journal Of The American Association For Geriatric Psychiatry, Volume: 20, No.: 12, Pages.: 1036-1044

Year of Publication



Objectives: Although many depressed patients with Alzheimer disease (AD) are treated with antidepressants, the effect of such treatment on cognitive performance in these patients is not known. The authors report cognitive outcomes in patients with depression of AD (dAD) after a 24-week trial of sertraline or placebo.; Design: Placebo-controlled, randomized, double-blind trial.; Setting: Outpatient memory clinics at five academic medical centers in the United States.; Participants: A total of 131 patients with dAD (60 men) and Mini-Mental State Examination scores of 10-26.; Intervention: Sertraline (n = 67), target dose of 100 mg daily or matching placebo (n = 64). Caregivers received standardized psychosocial intervention throughout the trial.; Measurements: Mini-Mental State Examination, cognitive subscale of the Alzheimer’s Disease Assessment Scale, letter fluency, backward digit span, Symbol Digit Modalities Test, and Finger Tapping Test, administered at baseline, and 8, 16, and 24 weeks following baseline.; Results: A series of linear models indicated no effect of treatment or of depression remission on cognitive test performance at 24 weeks. Regardless of treatment condition, very little change in cognitive test performance was noted in general.; Conclusions: Treatment with sertraline in patients with dAD is not associated with greater improvement in cognition at week 24 than treatment with placebo.;

Bibtex Citation

@article{Munro_2012, doi = {10.1097/jgp.0b013e31826ce4c5}, url = {}, year = 2012, month = {dec}, publisher = {Elsevier {BV}}, volume = {20}, number = {12}, pages = {1036--1044}, author = {Cynthia A. Munro and Crystal Flynn Longmire and Lea T. Drye and Barbara K. Martin and Constantine E. Frangakis and Curtis L. Meinert and Jacobo E. Mintzer and Anton P. Porsteinsson and Peter V. Rabins and Paul B. Rosenberg and Lon S. Schneider and Daniel Weintraub and Constantine G. Lyketsos}, title = {Cognitive Outcomes After Sertaline Treatment in Patients With Depression of Alzheimer Disease}, journal = {The American Journal of Geriatric Psychiatry} }


aged, aged, 80 and over, alzheimer disease, ambulatory care facilities, antidepressive agents, cognition, depressive disorder, doubleblind method, drug effects, drug therapy, etiology, female, humans, male, neuropsychological tests, pharmacology, psychology, sertraline, therapeutic use, treatment outcome

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Randomised Controlled Trial

Type of Outcomes

Cognition, Depression and Anxiety, Prevention and/or management of co-morbidities


Specialist Dementia Centre Care / Memory Clinic

Type of Interventions

Pharmaceutical Interventions, Treatment/prevention of co-morbidities or additional risks

Pharmaceutical Interventions

Antipsychotics and antidepressants


Depression / Prevention Management